Balaji Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.20 M
- Revenue Growth 258.85%
- Profit Growth 287.89%
- Ebitda 3789.05%
- Net Worth 87.31%
- Total Assets 146.54%
About Balaji Pharmachem
Balaji Pharmachem Private Limited (BPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 28 February 2020 (Four years and 11 months 26 days old ). Its registered office is in Panchkula, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹9.20 M.
Ashok Sharma and Rakesh Nag serve as directors at the Company.
Company Details
- Location
Panchkula, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304HR2020PTC085643
- Company No.
085643
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Feb 2020
- Date of AGM
24 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Balaji Pharmachem?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Nag  | Director | 28-Feb-2020 | Current |
| Ashok Sharma | Director | 28-Feb-2020 | Current |
Financial Performance of Balaji Pharmachem.
Balaji Pharmachem Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 258.85% increase. The company also saw a substantial improvement in profitability, with a 287.89% increase in profit. The company's net worth Soared by an impressive increase of 87.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Balaji Pharmachem?
In 2021, Balaji Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹9.20 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.92 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Mar 2022 | Others | ₹4.20 M | Open |
| 28 May 2021 | Others | ₹5.00 M | Open |
How Many Employees Work at Balaji Pharmachem?
Unlock and access historical data on people associated with Balaji Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Balaji Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Balaji Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.